Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy.

BACKGROUND C-reactive protein (CRP) is known to be a pathogenic agent in the cardiovascular system. However, the effect of CRP on heart failure has not been elucidated. The effect of human CRP on cardiac dysfunction induced by diabetes mellitus (DM) using human CRP-overexpressing transgenic mice (CRP-Tg) was examined. METHODS AND RESULTS DM was induced in male wild-type mice (Wt/DM) and CRP-Tg (CRP/DM) by an injection of streptozotocin. Non-diabetic wild-type mice (Wt/Con) and CRP-Tg (CRP/Con) served as controls. Echocardiography and hemodynamic measurements 6 weeks after injection showed lower fractional shortening and left ventricular (LV) dP/dt max in CRP/DM compared with Wt/DM. Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM. Nuclear staining of 8-hydroxydeoxyguanosine was also increased in CRP/DM compared with Wt/DM. CRP/DM was associated with increased terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling positive cells and a higher ratio of Bax/Bcl-2 proteins compared with Wt/DM. The extent of cardiac fibrosis assessed by Sirius red staining and immunohistochemical staining for collagen type 1 was significantly increased in CRP/DM compared with Wt/DM. CONCLUSIONS Overexpression of human CRP exacerbates LV dysfunction and remodeling in diabetic cardiomyopathy, possibly through enhancement of the inflammation, renin-angiotensin system, and oxidative stress.

[1]  S. Ogawa,et al.  Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. , 2010, American journal of physiology. Heart and circulatory physiology.

[2]  V. Hombach,et al.  Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? , 2009, Basic Research in Cardiology.

[3]  A. Ferreira,et al.  Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. , 2009, Journal of cardiac failure.

[4]  T. Walther,et al.  Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy , 2009, Diabetes.

[5]  M. Hori,et al.  Impact of diabetes mellitus on rehospitalization for heart failure among survivors of acute myocardial infarction in the percutaneous coronary intervention era. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[6]  Yasuhiro Hirasawa,et al.  Short-term amiodarone treatment attenuates the production of monocyte cytokines and chemokines by C-reactive protein and improves cardiac function in patients with idiopathic dilated cardiomyopathy and ventricular tachycardia. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[7]  E. Oda,et al.  Tentative cut point of high-sensitivity C-reactive protein for a component of metabolic syndrome in Japanese. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[8]  S. Yamada,et al.  Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. , 2008, Cardiovascular research.

[9]  S. Verma,et al.  Impaired endothelial function in C-reactive protein overexpressing mice. , 2008, Atherosclerosis.

[10]  S. Chakrabarti,et al.  PARP mediates structural alterations in diabetic cardiomyopathy. , 2008, Journal of molecular and cellular cardiology.

[11]  S. Prabhu,et al.  Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. , 2008, Journal of the American College of Cardiology.

[12]  C. Röcker,et al.  C‐reactive protein specifically binds to Fcγ receptor type I on a macrophage‐like cell line , 2008, European journal of immunology.

[13]  R. Goyal,et al.  Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats , 2008, Molecular and Cellular Biochemistry.

[14]  Carlos Orrego,et al.  Cytokines and acute heart failure , 2008, Critical care medicine.

[15]  S. Oparil,et al.  Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. , 2008, The American journal of pathology.

[16]  Ji-nan Zhang,et al.  C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes , 2008, Molecular and Cellular Biochemistry.

[17]  D. Katritsis,et al.  Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. , 2007, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[18]  C. Tschöpe,et al.  Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy , 2007, Basic Research in Cardiology.

[19]  A. Boyle,et al.  Angiotensin II and the cardiac complications of diabetes mellitus. , 2007, Current pharmaceutical design.

[20]  F. Qin,et al.  Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. , 2007, Free radical biology & medicine.

[21]  C. Tschöpe,et al.  Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy , 2007, Diabetes.

[22]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[23]  U. Laufs,et al.  Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy , 2007, Diabetologia.

[24]  John G F Cleland,et al.  Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. , 2007, American heart journal.

[25]  W. Hsueh,et al.  Recipes for creating animal models of diabetic cardiovascular disease. , 2007, Circulation research.

[26]  K. Sunagawa,et al.  Angiotensin II Type 1 Receptor Blocker Attenuates Myocardial Remodeling and Preserves Diastolic Function in Diabetic Heart , 2007, Hypertension Research.

[27]  I. Kola,et al.  Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice , 2007, Circulation.

[28]  K. Sunagawa,et al.  Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. , 2006, American journal of physiology. Heart and circulatory physiology.

[29]  S. Verma,et al.  C-Reactive Protein Alters Antioxidant Defenses and Promotes Apoptosis in Endothelial Progenitor Cells , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Brian Rodrigues,et al.  Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. , 2006, American journal of physiology. Heart and circulatory physiology.

[31]  A. Hofman,et al.  C-reactive protein and risk of heart failure. The Rotterdam Study. , 2006, American heart journal.

[32]  S. Verma,et al.  C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression in Human Endothelial Cells , 2006, Hypertension.

[33]  C. Tschöpe,et al.  Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus , 2006, Diabetologia.

[34]  D. Morrow,et al.  Is C-reactive protein an innocent bystander or proatherogenic culprit?: The Verdict Is Still Out , 2006, Circulation.

[35]  C. Yabe-Nishimura,et al.  Increased gene expression of glutathione peroxidase-3 in diabetic mouse heart. , 2006, Biological & pharmaceutical bulletin.

[36]  Sanjiv J. Shah,et al.  High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. , 2006, Journal of cardiac failure.

[37]  T. Walther,et al.  Transgenic activation of the kallikrein‐kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  U. Singh,et al.  C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[39]  S. Oparil,et al.  Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[41]  S. Ogawa,et al.  Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. , 2005, Cardiovascular research.

[42]  P. Ridker,et al.  C-reactive protein comes of age , 2005, Nature Clinical Practice Cardiovascular Medicine.

[43]  S. Ogawa,et al.  Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[44]  M. Rewers,et al.  Elevated C-reactive protein levels in the development of type 1 diabetes. , 2004, Diabetes.

[45]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[46]  Lan Li,et al.  C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.

[47]  D. Harrison,et al.  The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. , 2003, Trends in pharmacological sciences.

[48]  E. Edelman,et al.  Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.

[49]  S. Verma,et al.  C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.

[50]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[51]  L. Cai,et al.  Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. , 2002, Diabetes.

[52]  A. Szalai,et al.  Varied biologic functions of c-reactive protein , 2002, Immunologic research.

[53]  A. Maseri,et al.  Myocardial Cell Death in Human Diabetes , 2000, Circulation research.

[54]  C. Mold,et al.  C-Reactive Protein Binding to Murine Leukocytes Requires Fcγ Receptors1 , 2000, The Journal of Immunology.

[55]  C. Mold,et al.  C-reactive protein binding to murine leukocytes requires Fc gamma receptors. , 2000, Journal of immunology.

[56]  D. Bharadwaj,et al.  The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .

[57]  G. Stassi,et al.  Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. , 1999, Circulation.

[58]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[59]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.